Long-Term Data from Landmark Phase 3 Safety and Nutritional Study Evaluating Alnara Pharmaceuticals, Inc.' Liprotamase in Patients with CF to be Presented at 2009 North American Cystic Fibrosis Conference
Published: Oct 05, 2009
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnara Pharmaceuticals, Inc., a pharmaceutical company developing novel, non-systemic orally-delivered protein therapeutics for the treatment of metabolic diseases, announced today that results from a landmark, international Phase 3 study of the long-term safety and nutritional benefits of liprotamase for the treatment of pancreatic insufficiency in patients with cystic fibrosis (CF) will be presented at the 23rd Annual North American Cystic Fibrosis Conference (NACFC) being held October 15-17, 2009 in Minneapolis, Minnesota. Liprotamase is being developed in collaboration with the Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), a nonprofit affiliate of the Cystic Fibrosis Foundation. The 12-month study is the largest and longest prospective nutritional and safety study ever completed for a pancreatic enzyme replacement therapy (PERT).